[{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ AstraZeneca","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AB359","moa":"IL-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Wellington Management Company"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Series C Financing","leadProduct":"Etakafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AB821","moa":"IL-21 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Lonza Biologics Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"AB359","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Asher Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Asher Biotherapeutics \/ Asher Biotherapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Asher Biotherapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : As part of this collaboration agreement, Amgen will sponsor a global Phase 1b study to evaluate the early efficacy of AB248 (etakafusp alfa) in combination with Imdelltra in patients with ES-SCLC.

                          Product Name : AB248

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          January 08, 2025

                          Lead Product(s) : Etakafusp Alpha,Tarlatamab

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Amgen Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : As part of this agreement, AstraZeneca will operationalize a global study of AB248 (etakafusp alfa) as a first-line treatment in combination with rilvegostomig in patients with advanced NSCLC.

                          Product Name : AB248

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          January 07, 2025

                          Lead Product(s) : Etakafusp Alpha,Rilvegostomig

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : AB248, a novel IL-2 mutein fused to anti-CD8β antibody, is in Phase 1 trials as a CD8+ T cell selective IL-2 for cancer treatment.

                          Product Name : AB248

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          April 16, 2024

                          Lead Product(s) : Etakafusp Alpha,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : RA Capital Management

                          Deal Size : $55.0 million

                          Deal Type : Series C Financing

                          blank

                          04

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : AB248 is a novel CD8+ T cell selective IL-2, it selectively and potently activate CD8+ T-cells, while avoiding NK cells, which can act as pharmacological sink and contribute to toxicity, and regulatory T (Treg) cells, which are immunosuppressive.

                          Product Name : AB248

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          January 17, 2023

                          Lead Product(s) : Etakafusp Alpha,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : AB359, a CD8-targeted interleukin-2 (IL-2) immunotherapy for the treatment of chronic viral infections is potentially more tolerable and more active IL‑2-based therapy for the treatment of chronic HBV.

                          Product Name : AB359

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 21, 2022

                          Lead Product(s) : AB359

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : New preclinical data highlight the differentiated efficacy and safety profile of AB248, a fusion protein that selectively activates the IL-2 pathway in CD8+ T cells, which are key drivers of anti-tumor efficacy.

                          Product Name : AB248

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 03, 2022

                          Lead Product(s) : Etakafusp Alpha

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : AB248 demonstrated selectivity, with an approximately 1000-fold preference for the activation of CD8+ T cells over NK cells and Tregs, and induced dose-dependent, selective expansion of CD8+ T cells in non-human primates.

                          Product Name : AB248

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 04, 2022

                          Lead Product(s) : Etakafusp Alpha

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : AB248, Asher Bio’s lead cis-targeted immunotherapy, is a novel CD8-targeted IL-2 mutein designed to selectively activate interleukein-2 (IL-2) signaling on CD8+ T cells over natural killer cells and regulatory T (Treg) cells.

                          Product Name : AB248

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          May 10, 2022

                          Lead Product(s) : Etakafusp Alpha

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : Under the manufacturing agreement, Lonza will provide drug substance manufacturing for AB359 for preclinical and clinical testing.

                          Product Name : AB359

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          April 07, 2022

                          Lead Product(s) : AB359

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : Lonza Biologics Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : AB821, a CD8-IL21 cytokine has the potential to treat tumor types that may not be responsive to IL-2 and/or PD-1 therapy. PD-1-resistant tumors are associated with reduced memory T cell numbers and increased exhausted T cell numbers.

                          Product Name : AB821

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          March 11, 2022

                          Lead Product(s) : AB821

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank